Kangyuan Pharmaceuticals: ZX2021 is conducting Phase II clinical trials for overweight/obesity, with key progress expected to be made in Q4 of 2025.

Kangyuan Pharmaceuticals stated on the interactive platform that the company's innovative drug with three targets, ZX2021, and the dual-target drug ZX2010 are currently undergoing Phase II clinical trials. ZX2021 is undergoing a Phase II clinical trial targeting overweight/obesity, with a trial design of 24 weeks, and is expected to achieve key progress in weight loss and improvement of liver health in Q4 2025. ZX2010 is undergoing a Phase II clinical trial targeting type 2 diabetes, with an 18-week trial design, and is expected to achieve key progress in both blood sugar reduction and weight loss from Q4 2025 to Q1 2026.